187 results about "Bacterial vaginosis" patented technology

A pharmaceutical composition comprises (a) an antibacterial agent in an antibacterially effective amount, illustratively comprising clindamycin or a pharmaceutically acceptable salt or ester thereof, and (b) an antifungal agent in an antifungally effective amount, illustratively comprising butoconazole or a pharmaceutically acceptable salt or ester thereof. The composition is adapted for application in a unit dose amount to a vulvovaginal surface and has at least one nonlipoidal internal phase and at least one lipoidal external phase that is bioadhesive to the vulvovaginal surface. The composition is useful for administration to a vulvovaginal surface to treat a mixed bacterial vaginosis and vulvovaginal candidiasis infection.

A secretion-monitoring article for identifying a secreted biological fluid comprising a body with an absorbent material for absorbing a biological fluid secreted from a person and an indicator system. The indicator system comprises an indicator agent and an ion-balance reagent, wherein the indicator system provides an indication of physiological conditions associated with the pH or the buffer capacities of the biological fluid, which indication is stable for at least 48 hours, preferably at least 72 hours. The article can be embodied as a swab, gauze, shield, hygienic napkin, diaper or interlabial absorbent structure and can be used to indicate the presence of amniotic fluid, or secretions associated with bacterial vaginosis without giving a false positive result upon exposure to urine or drying out.

The present invention provides methods and compositions for identifying bacteria associated with bacterial vaginosis and diagnosing bacterial vaginosis in a subject.

The present invention provides a buffered non-flowing composition suitable for the treatment of bacterial vaginosis. The composition includes metronidazole in a concentration of about 0.50% (w/w) to about 1.50% (w/w). The metronidazole is present together with a buffer system in a physiologically tolerable medium. The buffer system provides an acidic buffered pH value for the composition in the range of about 5.0 to about 6.0. The present invention also provides for a method for inhibiting a microorganism. The method includes contacting a microorganism with an effective amount of the composition of the present invention, for a period of time effective to inhibit the microorganism. The present invention also provides for a method for treating bacterial vaginosis in a human patient. The method includes intravaginal administration to a patient in need of such treatment an effective amount of the composition the present invention. The composition is introduced into the vagina at least once a day for a time period of at least one day.

The present invention relates to methods for the diagnosis of bacterial vaginosis based on an analysis of a patient sample. For example, patient test samples are analyzed for the presence or absence of one or more lactobacilli and two or more pathogenic organisms. The presence or absence of one or more lactobacilli and two or more pathogenic organisms may be detected using PCR analysis of nucleic acid segments corresponding to each target organism. The quantity of the target organisms can then be used to determine a score which is indicative of a diagnosis of bacterial vaginosis.

There is disclosed a method for detecting the presence of bacterial vaginosis in a female subject comprising the steps of:

• • obtaining a sample from the vaginal region of the subject;
  • detecting acetic acid present in the sample; and
  • correlating the presence of detected acetic acid with the presence of bacterial vaginosis.

The invention relates to a test paper tape which can be used in the gynecological multiprogramming dry-chemistry joint detection. The test paper tape provided by the utility model comprises a dry-chemistry multiprogramming detection test paper tape which consists of a plastic substrate tape and various solidified regent blocks, and sample diluent. The dry regent blocks include combinations formed by increasing or decreasing at least three or more regent blocks of a Ph test regent block, a lactic acid regent block, a hydrogen peroxide concentration regent block, a leukocyte esterase concentration regent block, a neuraminidase activity regent block, an amine test regent block, a proline aminopeptidase substrate reagent block, an oxidase substrate reagent block, a N-acetylamine hexosidase substrate reagent block, a trichomonas specific protease substrate hydrolysis reagent block. the gynecological multiprogramming dry-chemistry joint detection test paper test provided by the utility model can detect Ph, lactic acid, hydrogen peroxide, leukocyte esterase, neuraminidase, amine test, proline aminopeptidase, oxidase, N-acetylamine hexosidase and trichomonas specific protease which are contained in leucorrhea sample at the same time, and can accurately reflect the microorganism environment of a women reproductive tract, the cleanness of leucorrhea secretion and the conditions of Candida albicans, trichomonas, gonococcus and the pathogens of bacterial vaginosis, thereby making the gynecological trichomonas detection more comprehensive; besides, the test paper tape provided by the utility model can be used easily and conveniently, and results can be obtained quickly. If the test paper tape is used together with a gynecological dry-chemistry analyzer, the operation can become easier and the result can be obtained more quickly.

A soft, pliable cellulose acetate phthalate (CAP)—hydroxypropyl cellulose (HPC) composite film is provided which is generated by casting from organic solvent mixtures containing ethanol. The film rapidly reduces the infectivity of several sexually transmitted disease pathogens, including the human immunodeficiency virus (HIV-1), herpesvirus (HSV), non-viral sexually transmitted disease pathogens (such as Neisseria gonorrhoeae, Haemophilus ducreyi, Chlamydia trachomatis and Treponema pallidum) and bacteria associated with bacterial vaginosis (BV). The film is converted into a gel/cream and thus does not have to be removed following application and use. In addition to being a topical microbicide, the film can be employed for the mucosal delivery of pharmaceuticals other than cellulose acetate phthalate.

A tablet for insertion into a vagina including 0.01 to 500 mg of a vaginal medication, such as a microbicide, such as cellulose acetate 1,2-benzenedicarboxylate (CAP); 100 to 500 mg of mannitol powder; 50 to 300 mg of inert microcrystalline cellulose; 10 to 80 mg of hydroxypropyl methylcellulose; 50 to 250 mg of glycerol and optionally 2 to 4 mg of at least one preservative which protects against microbicidal contamination and discourages the growth of yeast in the vagina. The tablet which includes CAP as the vaginal medication is vaginally administered before coitus in methods for preventing the sexual transmission of HIV-1, HIV-2, herpesvirus, or an infection caused by Neisseria gonorrhoeae, Chlamydia trachomatis, Trichomonas vaginalis, Haemophilus ducreyi or Treponema pallidum. The tablet which includes CAP as the vaginal medication is vaginally administered to prevent or treat bacterial vaginosis.

The present invention provides a non-toxic diagnostic composition for intravaginal monitoring of vaginal infections. The present invention further provides a diagnostic article for intravaginal monitoring of vaginal infections with the article including an absorbent material for absorbing vaginal secretions and a composition suitable for identification of the pH or the buffer capacities associated with vaginal secretions. The diagnostic composition provides a visible indication of vaginal infections, such as bacterial vaginosis.

The invention relates generally to pharmaceutical compositions comprising rifaximin effective at treating vaginal infections, and in particular bacterial vaginosis. The pharmaceutical compositions comprising rifaximin granules are characterized in that they release rifaximin in the vagina in a controlled way. The present invention also relates to processes for preparation of the rifaximin pharmaceutical compositions and their use in the treatment of vaginal infections. Effective dosages and courses of treatment useful and effective at recovering from the disease and preventing any possible relapse are also provided.

The invention aims to provide a combined detection kit for vaginitis, capable of evaluating vaginal micro-ecological environment, vaginal cleanliness, and pathogens of bacterial vaginosis, Candida vaginitis, trichomonas vaginitis of the tested person simultaneously. Ihe following technical scheme adopted by the invention, a combined detection kit for vaginitis is provided and comprises a reaction device, diluent and chromogenic liquid, the reaction device is a hole type box-shaped reaction device with six reacting blind holes, in which a hydrogen peroxide concentration detection reagent pad, a leukocyte esterase detection reagent pad, a neuraminidase detection reagent pad, a proline aminopeptidase detection reagent pad, an acetyl glucosaminidase detection reagent pad and pH detection test paper are arranged respectively. Through the combined detection, the vaginitis caused by most of the BV (Bacterial Vaginosis) pathogens, the Candida albicans and the trichomonas can be detected, BV missing detection caused by the simple detection for one kind of enzyme activity is avoided largely, and the detection reliability and accuracy are increased.

The invention belongs to the technical field of biomedicine, and in particular relates to the application of cathelicidin-BF, an antibacterial peptide of ceratopsia, in the preparation of medicines for treating bacterial vaginosis. The antibacterial peptide cathelicidin-BF of the present invention has the beneficial characteristics of strong bactericidal effect and rapid sterilization on Staphylococcus aureus and Escherichia coli in vitro; the effect of cathelicidin-BF on vaginitis caused by E. The results of coccus-infected vaginitis are basically the same, and it can significantly inhibit Staphylococcus aureus or Escherichia coli in the vagina, and cathelicidin-BF has an obvious effect of reducing inflammation; it can be used in the preparation of drugs for treating bacterial vaginosis.

The invention discloses a vaginitis test kit which comprises a reaction device, a sampling test tube, a straw, joint test diluent, joint test chromogenic reagent, joint test stop solution, a user manual and a joint test colourimetric card, wherein a hydrogen peroxide reaction hole, a leukocyte esterase reaction hole, a sialic acid glucoside enzyme reaction hole, a beta- glucuronic acid enzyme reaction hole, a P glucosidase reation hole and a pH value hole; relevant reaction bases are arranged in the reaction holes; reach reaction base comprises a corresponding reaction substrate curing layer,a chromogenic promotional layer and a chemical inert carrier layer. The invention also provides a preparation method of the test kit and the preparation method of a novel chemical carrier. The test kit can be used for distinguishing bacterial vaginosis and vaginitis, and can further identify aerobic/anaerobic bacteria, facultative anaerobic bacteria and other flora in vaginal secretion. The method is simple and quick to operate, has high accuracy, and is applicable to clinical practice, particularly hospital outpatient practice.

The invention relates to the fields of computational biology and medical health, and mainly aims at personalized precise diagnosis and health assessment of diseases called "microbial flora-related diseases", such as the disease of the digestive tract, bacterial vaginosis and periodontitis. An assessment method based on the microbial interaction network analysis of the human microbial flora is disclosed and validated. Specifically, the above diagnostic or assessment purpose is realized by detecting and monitoring the ratio of positive effects to negative effects in a human microbial interactionnetwork. By analyzing the microbial flora data of the human body including intestines, vagina, lungs, mouth and various parts of the skin, the inventor found that the ratio of positive effects to negative effects in the microbial interaction network of patients and that in the microbial interaction network of healthy people (ie, P/N ratio) are significantly different. Therefore, an effective detection index and implementation technology can be provided for personalized precise diagnosis of "microbial flora-related diseases", and at the same time, reliable reference indicators and technical support can be provided for assessing the disease risk of healthy people.

The invention discloses lactobacillus jensenii and application thereof. The lactobacillus jensenii is particularly lactobacillus jensenii IMJ-1, and the file No. of the lactobacillus jensenii IMJ-1 in the General Microbiological Culture Collection Center of China Microbial Culture Collection Management Committee is CGMCC No. 6558. The lactobacillus jensenii IMJ-1 CGMCC No.6558 has high H2O2 generation capability, can effectively suppress breeding of external pathogenic bacteria and other conditional pathogenic bacteria, and has a high binding function to epithelial cells of vagina, and accordingly, breeding of bacteria strains on the vaginal epithelium is guranteed. Besides, the lactobacillus jensenii IMJ-1 CGMCC No. 6558 has a certain application prospect in preventing and curing bacterial vaginosis.

The present invention discloses Lactobacillus crispatus 262-1 and an inoculum comprising such strain and application thereof. The Lactobacillus crispatus 262-1 is a new strain of Lactobacillus genus and is preserved in the China General Microbiological Culture Collection Center with a preservation number of CGMCC No. 6469. The Lactobacillus crispatus 262-1 particularly is the dominant bacteria in the vagina, has good acid and H₂O₂ production capability, good adhesion to the vaginal epithelial cells and significant resistance to bacterial vaginosis and various vaginal infections, and is characterized by safety, non-toxicity, good stability and long term preservation. The present invention also relates to the use of the Lactobacillus crispatus 262-1 in the preparation of pharmaceuticals for preventing and/or treating gynecological diseases and its application in feminine care products such as medical instruments, disinfect products or cosmetics.